Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

SRTS US Equity

Sensus Healthcare, Inc.Health Care · Surgical & Medical Instruments & Apparatus · CIK 1494891 · FY ends Dec 31
$3.00
+0.10 (+3.45%)
USD · as of 2026-08-18 · marketstack
3 registered studies · 0 active

Studies where SRTS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

3 observational · 1 with posted results

Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC) · FINRA short interest 10.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Superficial Radiation Therapy (SRT) for the Treatment of Recurrent Keloid ScarsNCT04184011observationalIncidence of keloid recurrence rates.Unknown statusDevice: SRT-100™Keloid Scar1002020-08-162019-12-03
A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)NCT03693937results2019-07-05observationalCure RateStudy Protocol and Statistical Analysis PlanCompletedRadiation: SRT-100Non-melanoma Skin Cancer7762019-03-16actual2019-07-05
A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Keloid Scars.NCT03693924observationalLong-term recurrence rateUnknown statusRadiation: SRT-100Keloid Scar1002019-02-162018-10-03

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19